Nearly 21 million persons in the US have diabetes. About 5-10% of them have type 1 diabetes, which develops as a consequence of the body's failure to produce insulin. Most others have type 2 diabetes, which develops because of the body's failure to properly use the insulin it produces. Projections on the future burden of diabetes suggest that the prevalence will increase 165% between 2000 and 2050, with the greatest increases in the population over 75 years old and among African-Americans [1] . Children are also increasingly affected by diabetes. Most of the increase in the prevalence of diabetes in children and adults is attributable to the alarming rise in obesity.
The new Kidney Disease Outcomes Quality Initiative (KDOQI TM ) Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and CKD were developed by the National Kidney Foundation (NKF) to improve outcomes in patients with diabetes and CKD by providing strategies for the diagnosis and management of CKD in the setting of diabetes. The guidelines will be published in 2007 as a supplement to the American Journal of Kidney Diseases [4] . Since this review was submitted prior to publication of the guidelines and recommendations, some portions may differ slightly from the published report.
The work group that developed the guidelines and recommendations consisted of individuals with expertise in nephrology, diabetology and endocrinology, pharmacology, social work, nursing and nutrition. They were assisted by an evidence review team with expertise in systematic review of the medical literature. The members of these groups are listed in table 1 . Evidence for clinical practice guidelines was derived from a systematic summary of the available scientific literature. When sufficient evidence was lacking, clinical practice recommendations were developed that reflect expert opinion.
The target patient population for this clinical practice guideline is those with CKD stages 1-5, including dialysis and transplant patients ( table 2 ). The emphasis of the guideline, however, is on stages 1-4, since the evidence in stage 5 is either lacking or addressed in other NKF-KDOQI TM guidelines. Consideration is given to the diagnosis, impact, and management of diabetes and CKD in children, adults, the elderly, pregnant women, and in different racial and ethnic groups. The intended readers are practitioners who manage patients with diabetes and CKD, including, but not limited to, primary care providers, nephrologists, diabetologists and endocrinologists, cardiologists, nurse practitioners and physician's assistants, nurses, dietitians, and diabetes educators. The guidelines describe the process for screening and diagnosis of kidney disease in the setting of diabetes and the management of diabetes and CKD, including the management of hyperglycemia and general diabetes care, hypertension, dyslipidemia, and nutrition. Special topics such as the management of albuminuria in the normotensive diabetic patient and the potential value of albuminuria as a marker of treatment efficacy; the impact of diabetes and CKD in special populations, including minorities and pregnant women; the importance of behavioral self-management, and the value of intensive multifaceted intervention in these high risk patients are also addressed as recommendations.
The new guidelines update and extend the scope of the NKF-KDOQI TM Clinical Practice Guidelines that presently offer strategies to identify CKD [2] and manage hypertension [5] , dyslipidemia [6] , bone disease [7] , anemia [8] , nutrition [9] , and cardiovascular disease [10] in patients with CKD.
